Logo image of ADMA

ADMA BIOLOGICS INC (ADMA) Stock Overview

NASDAQ:ADMA - US0008991046 - Common Stock

16.87 USD
-0.04 (-0.21%)
Last: 9/5/2025, 8:00:01 PM
16.87 USD
0 (0%)
After Hours: 9/5/2025, 8:00:01 PM

ADMA Key Statistics, Chart & Performance

Key Statistics
52 Week High25.67
52 Week Low13.5
Market Cap4.03B
Shares238.63M
Float229.09M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.54
PE31.24
Fwd PE18.28
Earnings (Next)11-05 2025-11-05
IPO10-17 2013-10-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ADMA short term performance overview.The bars show the price performance of ADMA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

ADMA long term performance overview.The bars show the price performance of ADMA in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400 500

The current stock price of ADMA is 16.87 USD. In the past month the price increased by 0.72%. In the past year, price increased by 3.75%.

ADMA BIOLOGICS INC / ADMA Daily stock chart

ADMA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.07 375.50B
AMGN AMGEN INC 13.01 152.70B
GILD GILEAD SCIENCES INC 14.86 142.76B
VRTX VERTEX PHARMACEUTICALS INC 23.38 101.56B
REGN REGENERON PHARMACEUTICALS 12.56 60.77B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 80.99 45.95B
ONC BEONE MEDICINES LTD-ADR 6.89 40.63B
INSM INSMED INC N/A 30.67B
BNTX BIONTECH SE-ADR N/A 27.03B
NTRA NATERA INC N/A 23.06B
BIIB BIOGEN INC 8.79 20.62B

About ADMA

Company Profile

ADMA logo image ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 677 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Company Info

ADMA BIOLOGICS INC

465 State Route 17

Ramsey NEW JERSEY 07446 US

CEO: Adam S. Grossman

Employees: 677

ADMA Company Website

ADMA Investor Relations

Phone: 12014785552

ADMA BIOLOGICS INC / ADMA FAQ

What is the stock price of ADMA BIOLOGICS INC today?

The current stock price of ADMA is 16.87 USD. The price decreased by -0.21% in the last trading session.


What is the ticker symbol for ADMA BIOLOGICS INC stock?

The exchange symbol of ADMA BIOLOGICS INC is ADMA and it is listed on the Nasdaq exchange.


On which exchange is ADMA stock listed?

ADMA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ADMA BIOLOGICS INC stock?

10 analysts have analysed ADMA and the average price target is 29.64 USD. This implies a price increase of 75.7% is expected in the next year compared to the current price of 16.87. Check the ADMA BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ADMA BIOLOGICS INC worth?

ADMA BIOLOGICS INC (ADMA) has a market capitalization of 4.03B USD. This makes ADMA a Mid Cap stock.


How many employees does ADMA BIOLOGICS INC have?

ADMA BIOLOGICS INC (ADMA) currently has 677 employees.


What are the support and resistance levels for ADMA BIOLOGICS INC (ADMA) stock?

ADMA BIOLOGICS INC (ADMA) has a support level at 16.63 and a resistance level at 17.69. Check the full technical report for a detailed analysis of ADMA support and resistance levels.


Is ADMA BIOLOGICS INC (ADMA) expected to grow?

The Revenue of ADMA BIOLOGICS INC (ADMA) is expected to grow by 19.81% in the next year. Check the estimates tab for more information on the ADMA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ADMA BIOLOGICS INC (ADMA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ADMA BIOLOGICS INC (ADMA) stock pay dividends?

ADMA does not pay a dividend.


When does ADMA BIOLOGICS INC (ADMA) report earnings?

ADMA BIOLOGICS INC (ADMA) will report earnings on 2025-11-05.


What is the Price/Earnings (PE) ratio of ADMA BIOLOGICS INC (ADMA)?

The PE ratio for ADMA BIOLOGICS INC (ADMA) is 31.24. This is based on the reported non-GAAP earnings per share of 0.54 and the current share price of 16.87 USD. Check the full fundamental report for a full analysis of the valuation metrics for ADMA.


What is the Short Interest ratio of ADMA BIOLOGICS INC (ADMA) stock?

The outstanding short interest for ADMA BIOLOGICS INC (ADMA) is 6.53% of its float. Check the ownership tab for more information on the ADMA short interest.


ADMA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ADMA. When comparing the yearly performance of all stocks, ADMA is a bad performer in the overall market: 82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ADMA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ADMA. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ADMA Financial Highlights

Over the last trailing twelve months ADMA reported a non-GAAP Earnings per Share(EPS) of 0.54. The EPS increased by 285.71% compared to the year before.


Industry RankSector Rank
PM (TTM) 44.06%
ROA 37.42%
ROE 52.45%
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%7.69%
Sales Q2Q%13.8%
EPS 1Y (TTM)285.71%
Revenue 1Y (TTM)43.58%

ADMA Forecast & Estimates

10 analysts have analysed ADMA and the average price target is 29.64 USD. This implies a price increase of 75.7% is expected in the next year compared to the current price of 16.87.

For the next year, analysts expect an EPS growth of 16.79% and a revenue growth 19.81% for ADMA


Analysts
Analysts82
Price Target29.64 (75.7%)
EPS Next Y16.79%
Revenue Next Year19.81%

ADMA Ownership

Ownership
Inst Owners90.24%
Ins Owners2.35%
Short Float %6.53%
Short Ratio4.86